Show simple item record

dc.contributor.authorJames, N
dc.contributor.authorSpears, M
dc.contributor.authorClarke, Noel W
dc.contributor.authorDearnaley, D
dc.contributor.authorDe Bono, J
dc.contributor.authorGale, J
dc.contributor.authorHetherington, J
dc.contributor.authorHoskin, P
dc.contributor.authorJones, R
dc.contributor.authorLaing, R
dc.contributor.authorLester, J
dc.contributor.authorMcLaren, D
dc.contributor.authorParker, C
dc.contributor.authorParmar, M
dc.contributor.authorRitchie, A
dc.contributor.authorRussell, J
dc.contributor.authorStrebel, R
dc.contributor.authorThalmann, G
dc.contributor.authorMason, M
dc.contributor.authorSydes, M
dc.date.accessioned2014-11-04T10:52:01Z
dc.date.available2014-11-04T10:52:01Z
dc.date.issued2014-10-06
dc.identifier.citationSurvival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). 2014: Eur Urolen
dc.identifier.issn1873-7560
dc.identifier.pmid25301760
dc.identifier.doi10.1016/j.eururo.2014.09.032
dc.identifier.urihttp://hdl.handle.net/10541/333689
dc.description.abstractProstate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa-the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)-includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to European urologyen
dc.titleSurvival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019).en
dc.typeArticleen
dc.contributor.departmentUniversity of Warwick, Coventry, UK.en
dc.identifier.journalEuropean Urologyen
html.description.abstractProstate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa-the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)-includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort.


Files in this item

This item appears in the following Collection(s)

Show simple item record